Screener
CRISPR Therapeutics CRSP Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Total other income, net | 8,156 | 13,537 |
| Net loss before income taxes | (122,092) | (134,887) |
| Provision for income taxes | (839) | (1,109) |
| Net loss | (122,931) | (135,996) |
| Foreign currency translation adjustment | (32) | 41 |
| Unrealized (loss) gain on marketable securities | (6,730) | 2,254 |
| Comprehensive loss | $(129,693) | $(133,701) |
| Net loss per common share — basic | $(1.28) | $(1.58) |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's net income?
- CRISPR Therapeutics (CRSP) reported net income of -$122.93M in Q1 2026.
- How has CRISPR Therapeutics's net income changed year-over-year?
- CRISPR Therapeutics's net income increased by 9.6% year-over-year, from -$136M to -$122.93M.
- What is the long-term trend for CRISPR Therapeutics's net income?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's net income has grown at a -5.4% compound annual growth rate (CAGR), from -$650.18M to -$581.6M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about CRISPR Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude